GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Cash Flow from Investing

Gain Therapeutics (Gain Therapeutics) Cash Flow from Investing : $11.14 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Gain Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $3.02 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Gain Therapeutics gained $3.02 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Gain Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Gain Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gain Therapeutics Cash Flow from Investing Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -0.01 -0.02 -0.09 -14.78 10.22

Gain Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.11 3.05 1.93 3.14 3.02

Gain Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Gain Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Gain Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gain Therapeutics  (NAS:GANX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Gain Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Gain Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Gain Therapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Gain Therapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Gain Therapeutics's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Gain Therapeutics's sale of investment for the three months ended in Mar. 2024 was $3.02 Mil. It means Gain Therapeutics gained $3.02 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Gain Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Gain Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Gain Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Gain Therapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics paid $0.00 Mil for other investing activities.


Gain Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Gain Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Gain Therapeutics (Gain Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.
Executives
Matthias Alder officer: Chief Operating Officer C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne officer: Chief Financial Officer 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta officer: Principal Accounting Officer C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Salvatore Calabrese officer: Chief Financial Officer C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Goldstein Dov A Md director
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Claude Nicaise director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto officer: President and General Manager C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814

Gain Therapeutics (Gain Therapeutics) Headlines

From GuruFocus

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 07-02-2022